Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 4

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-028 Check this box if no longer subject to Section 16. Form 4 or Form 5 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES OMB Number: SECURITIES Expires: 200 Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 S. Relationship of Reporting Person(s) to Issuer (Print or Type Responses) 1. Name and Address of Reporting Person* Huizenga Theodore Alan 2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE] 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year)	STATES SECURITIES AND EXCHANGE COMMISSION				
Washington, D.C. 20549 OMB 3235-026 Washington, D.C. 20549 Check this box if no longer subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF Section 16. Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. Section 17(a) of the Public Utility Holding Company Act of 1940 (Print or Type Responses) 1. Name and Address of Reporting Person* 1. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE] (Check all applicable) (Last) (First) (Middle) O/2025/2016 C/O ULTRAGENYX PHARMACEUTICAL INC., 60	STATES SECURITIES AND EXCHANGE COMMISSION				
if no longer subject to Section 16. STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: 200 200 Estimated average burden hours per response Form 4 or Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, section 17(a) of the Public Utility Holding Company Act of 1935 or Section 16. 0 (Print or Type Responses) 30(h) of the Investment Company Act of 1940 1(b). 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person* Huizenga Theodore Alan 2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE] 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director Officer (give title 10% Owner Other (specify below) C/O ULTRAGENYX 05/25/2016 Obj 25/2016 Controller and PAO	Washington, D.C. 20549	3235-02	287		
subject to Section 16. SECURITIES Estimated average burden hours per response Form 4 or Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. See Instruction 30(h) of the Investment Company Act of 1940 1000 (Print or Type Responses) 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Check all applicable) C/O ULTRAGENYX 05/25/2016 05/25/2016 Controller and PAO		Exhirds.			
Form 5 obligations may continue. See Instruction 1(b). Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b). (Print or Type Responses) 30(h) of the Investment Company Act of 1940 1(b). 1. Name and Address of Reporting Person [*] Huizenga Theodore Alan 2. Issuer Name and Ticker or Trading Symbol Ultragenyx Pharmaceutical Inc. [RARE] 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 5. The Company Act of 1935 or Section C/O ULTRAGENYX 05/25/2016 05/25/2016 Director below) 10% Owner controller and PAO	SECURITIES	Estimated average burden hours per			
1. Name and Address of Reporting Person * Huizenga Theodore Alan 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Person(s) to Issuer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 3. Date of Earliest Transaction (Month/Day/Year) 5. Relationship of Reporting Person(s) to Issuer	Form 5 obligations may continue. See Instruction Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940				
Huizenga Theodore Alan Symbol Issuer Ultragenyx Pharmaceutical Inc. (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) C/O ULTRAGENYX 05/25/2016 Of/25/2016 Controller and PAO					
[RARE] (Check all applicable) (Last) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director Officer (give title below) 10% Owner Officer (give title below) C/O ULTRAGENYX 05/25/2016 Controller and PAO	Symbol Issuer				
C/O ULTRAGENYX 05/25/2016 Officer (give title below) Other (specify below) PHARMACEUTICAL INC., 60 05/25/2016 Controller and PAO	C Check	k all applicable)			
C/O ULTRAGENYX 05/25/2016 Controller and PAO PHARMACEUTICAL INC., 60	(Month/Dav/Year) Officer (give tit	title Other (specify			
LEVERONICOURI	05/25/2016 Contro	· · · · · · · · · · · · · · · · · · ·			
(Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) 6. Individual or Joint/Group Filing(Check	-	pint/Group Filing(Check			
NOVATO, CA 94949 _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person	Form filed by Mor				
(City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned	(Zip) Table I - Non-Derivative Securities Acquired, Disposed of,	f, or Beneficially Owned			
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3.4. Securities TransactionAcquired (A) or Disposed of (D) (Instr. 3, 4 and 5)5. Amount of Securities6. Ownership Form: Direct7. Nature of Indirect0. (Instr. 3)2. Transaction Date, if any (Month/Day/Year)3.4. Securities TransactionAcquired (A) or Ode5. Amount of Securities6. Ownership Form: Direct7. Nature of Indirect0. (Instr. 3)0. (Month/Day/Year)(Instr. 8)(Instr. 3, 4 and 5)0. (Month0. (Instr. 4)0. (Instr. 4)(Instr. 4)(Instr. 4)(Instr. 4)) Execution Date, if TransactionAcquired (A) or Securities For any Code Disposed of (D) Beneficially (D (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5) Owned In Following (D Reported	Form: Direct Indirect (D) or Beneficial Indirect (I) Ownership			
(A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price	(A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price				
Common 05/25/2016 A $5,000$ A \$ 0 9,334 (2) D Stock (1) A \$ 0 9,334 (2) D		D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exer Expiration D (Month/Day	ate	7. Title and Underlying 5 (Instr. 3 and	Securities
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	\$ 68.59	05/25/2016		A	10,000	<u>(3)</u>	05/25/2026	Common Stock	10,000

Edgar Filing: Ultragenyx Pharmaceutical Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Huizenga Theodore Alan C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO, CA 94949			Controller and PAO			

Signatures

/s/ Shalini Sharp by power of attorney for Theodore A. Huizenga	05/27/2016				
**Signature of Reporting Person	Date				
Explanation of Responses:					

If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Award of Restricted Stock Units under the Company's 2014 Incentive Plan that vests with respect to 1/4 of the underlying shares on each anniversary of the grant date such that the Restricted Stock Units are fully vested on the fourth anniversary of the grant date.
- (2) Includes shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions.
- (3) The options shall vest with respect to 1/4th of the underlying shares on the first anniversary of the grant date and then with respect to 1/4th of the underlying shares monthly thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.